Pharma Business - September 17, 2015
Restructuring at Medivir
Medivir will merge its Research and Development unit and implement changes within the management Group. The company has announces that, as the next step in the company’s optimisation process, its research and development operations will be merged into a joint unit as of 1 October 2015, headed by Richard Bethell who will hold the new title […]
Financing - May 7, 2015
Medivir Bd. to Repurchase Shares
Medivir AB’s board of directors plans to use the authorization given at the annual general meeting to repurchase class B company shares. The repurchases will be carried out in batches over time, but will conclude prior to the next annual general meeting. The execution of the repurchases will depend on market conditions, according to BioSpace.com, […]
Clinical Trials - April 8, 2015
Positive Data for Hepatitis Drug
New clinical data for Medivir AB’s once-daily HCV protease inhibitor simeprevir were presented at the 24th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Istanbul, Turkey, recently. Six oral and poster presentations were held on three clinical studies involving several development programs including simeprevir in different treatment combinations, durations […]
